Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Rodney P,Rocconi

第一单位： University of South Alabama - Mitchell Cancer Institute, Mobile, AL, USA.

作者： Rodney P,Rocconi ^[1] ; Erin E,Stevens ^[2] ; Justin N,Bottsford-Miller ^[2] ; Sharad A,Ghamande ^[3] ; Jeffrey,Elder ^[4] ; Leslie L,DeMars ^[5] ; Adnan,Munkarah ^[6] ; Phylicia,Aaron ^[7] ; Laura,Stanbery ^[7] ; Gladice,Wallraven ^[7] ; Ernest,Bognar ^[7] ; Meghan,Manley ^[7] ; Staci,Horvath ^[7] ; Luisa,Manning ^[7] ; Adam,Walter ^[8] ; Evanthia,Galanis ^[9] ; Thomas,Herzog ^[10] ; Bradley J,Monk ^[11] ; Robert L,Coleman ^[12] ; John,Nemunaitis ^[13]

作者单位： University of South Alabama - Mitchell Cancer Institute, Mobile, AL, USA. ^[1] Billings Clinic, Billings, MT, USA. ^[2] Augusta University, Augusta, GA, USA. ^[3] Greenville Health System, Greenville, SC, USA. ^[4] Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. ^[5] Josephine Ford Cancer Institute, Detroit, MI, USA. ^[6] Gradalis, Inc., Dallas, TX, USA. ^[7] ProMedica, Toledo, OH, USA. ^[8] Mayo Clinic, Rochester, MN, USA. ^[9] University of Cincinnati Cancer Center, Cincinnati, OH, USA. ^[10] Arizona Oncology, Phoenix, AZ, USA. ^[11] MD Anderson Cancer Center, Houston, TX, USA. ^[12] Gradalis, Inc., Dallas, TX, USA. jnemunaitis@gradalisinc.com. ^[13]

主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);女(雌)性(Female);人类(Humans);肿瘤复发, 局部(Neoplasm Recurrence, Local);卵巢肿瘤(Ovarian Neoplasms)

DOI 10.1038/s41417-021-00317-5

PMID 33753870

发布时间 2022-10-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交